Welcome
to Tristan a Consortium for validating Translational
Imaging in Drug Safety Assessment

Our approach

We are using imaging techniques to improve drug safety analysis. This needs thorough validation of imaging procedures as “biomarkers”. This will help drug developers to bring new, safer drugs to the market and thereby enable doctors to treat their patients more effectively.

Learn more about the TRISTAN approach

Liver transporter assessment

How we will help to improve detection of drug side effects that harm the liver.

Learn more

Assessment
of Diild

Improving imaging biomarkers to detect and understand potential drug side effects in the lung.

Learn more

Biologics-
PET

Improve analysis of bio-distribition of biologics by optimized PET imaging to aid reducing drug side effects.

Learn more

Our partners

Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide
Slide

Latest Posts

DIILD Review

15.10.2018

Drug-Induced Interstitial Lung Disease: A Systematic Review

Read more

First clinical DIILD study is live

TRISTAN's first clinical study is now up and running, with patients being recruited from across the North of England. The TRISTAN-ILD study aims to assess the utility of MRI and CT methods in the identification of drug-induced interstitial lung disease

Read More

Get in touch

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116106. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA